arrow_back Back to App

Drug Price Transparency: Advertisements Must Disclose Wholesale Costs

This law mandates that direct-to-consumer advertisements for prescription drugs must include the Wholesale Acquisition Cost (WAC). This aims to help citizens estimate potential treatment costs, particularly for those with high-deductible health plans who often pay the full list price initially. The change promotes informed decision-making regarding health and personal finances before consulting a doctor.
Key points
Drug manufacturers must clearly disclose the Wholesale Acquisition Cost (WAC) for a 30-day supply in all direct-to-consumer advertisements.
This requirement applies only to drugs costing $35 or more for a 30-day supply.
Citizens gain better insight into the actual cost of advertised medications, aiding financial planning and choice of treatment.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_5958
Sponsor: Rep. Spanberger, Abigail Davis [D-VA-7]
Process start date: 2023-10-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug-price Transparency for Consumers Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_5958.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-10-25.

What are the main provisions?

Key points include:

  • Drug manufacturers must clearly disclose the Wholesale Acquisition Cost (WAC) for a 30-day supply in all direct-to-consumer advertisements.
  • This requirement applies only to drugs costing $35 or more for a 30-day supply.
  • Citizens gain better insight into the actual cost of advertised medications, aiding financial planning and choice of treatment.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Spanberger, Abigail Davis [D-VA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Economy